GBT Global Blood Therapeutics, Inc.

30.50
0  0%
Previous Close 30.55
Open 30.60
Price To book 6.01
Market Cap 1.33B
Shares 43,534,000
Volume 781,152
Short Ratio 1.57
Av. Daily Volume 1,547,750

SEC filingsSee all SEC filings

  1. 8-K - Current report 17725688
  2. 8-K - Current report 17707406
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17685392
  4. 8-K - Current report 17685286
  5. 8-K - Current report 17642299

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initiated November 2016.
GBT440
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Announced January 18, 2017 that Phase 3 enrollment has commenced. Previous guidance is for top-line data due 1H 2019.
GBT440 - HOPE
Sickle cell disease in adults
Phase 2a initiated June 2016. Data due 2017
GBT440
Idiopathic pulmonary fibrosis (IPF)
Phase 2a initiated June 2016. Data due 2017
GBT440
Sickle cell disease in adolescents

Latest News

  1. 5 Top Performing Stocks of the Best ETF of Q1
  2. Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
  3. Market Is Home on the Range Again
  4. Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion
  5. 5 Stocks The Best Performing Hedge Funds Are Piling Into
  6. Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment
  7. Global Blood reports 4Q loss
  8. Market Takes 'National Napping Day' Seriously
  9. Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results
  10. Biotech Leads the Way Again Today
  11. These 3 Stocks Have Doubled Investors' Money
  12. Late Market Rally but No Bounce for Bulls
  13. Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
  14. Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors
  15. Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning
  16. Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT)
  17. Market Set Up for Oversold Bounce
  18. Company News for March 09, 2017
  19. 7 Stocks Trending Up With Monster Volume
  20. Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk

SEC Filings

  1. 8-K - Current report 17725688
  2. 8-K - Current report 17707406
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17685392
  4. 8-K - Current report 17685286
  5. 8-K - Current report 17642299
  6. 424B5 - Prospectus (Rule 424(b)(5)) 17629689
  7. 8-K - Current report 17629683
  8. 424B5 - Prospectus (Rule 424(b)(5)) 17625032
  9. 8-K - Current report 17619774
  10. 8-K - Current report 17619773